Sangamo BioSciences, Inc. (NASDAQ:SGMO) had its price target upped by Wedbush to $22.00 in a research note issued to investors on Thursday, AR Network reports. Sangamo Biosciences, Inc. (NASDAQ:SGMO) stock opened at $18.68 in last trading session, and closed at $19.07, trading in the range of $18.21 – $19.40. The stock showed a positive weekly performance of 40.63%.
Oncomed Pharmaceuticals Inc (NASDAQ:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that data from ongoing clinical trials of two novel anti-cancer stem cell therapeutics, both targeting the Notch cancer stem cell pathway and being evaluated in advanced pancreatic cancer, have been accepted for presentation at the upcoming 2014 Gastrointestinal Cancers Symposium being held January 16-18, 2014 at the Moscone West Convention Center in San Francisco, California. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) shares closed at $37.38 on last trade day, by gaining 9.94%. Stock 52 week range is $12.06 – $37.85. Company’s market capitalization is $1.04 billion.
Mallinckrodt plc (MNK) announced that its co-promotion agreement with Zogenix, Inc. (NASDAQ:ZGNX) for SUMAVEL DosePro, approved for the treatment of adults suffering from acute migraine and cluster headaches, will be terminated. Mallinckrodt will stop promoting the drug from Jan 31. The agreement between Mallinckrodt and Zogenix dates back to Jun 7, 2012. Zogenix, Inc. (NASDAQ:ZGNX) stock advanced 7.21% and finished the last session at $4.31. The EPS of the stock remained -0.44. Company’s market capitalization is $596.65 million.
Piper Jaffray is raising its price target on Galena Biopharma to $7 from $2.75, citing an increased forecast for sales of Abstral, which Galena acquired in March and launched in October. Piper raised its Abstral sales forecast for 2014 to $16.5M from $10M, a run-rate at which the firm says the Abstral business could turn a profit, and the firm maintains an Overweight rating on shares. Galena Biopharma Inc (NASDAQ:GALE) stock opened at $6.38 in last trading session and closed at $6.35. The 52 week range of the stock is $1.65 – $6.84 and the day range was $6.08 – $6.48.